{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T21:19:52Z","timestamp":1773695992530,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T00:00:00Z","timestamp":1580860800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T00:00:00Z","timestamp":1580860800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100005357","name":"Agent\u00fara na Podporu V\u00fdskumu a V\u00fdvoja","doi-asserted-by":"publisher","award":["VEGA 1\/0873\/18"],"award-info":[{"award-number":["VEGA 1\/0873\/18"]}],"id":[{"id":"10.13039\/501100005357","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s10238-020-00612-9","type":"journal-article","created":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T14:03:48Z","timestamp":1580911428000},"page":"277-287","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Systemic treatment of the metastatic renal cell carcinoma: usefulness of the apparent diffusion coefficient of diffusion-weighted MRI in prediction of early therapeutic response"],"prefix":"10.1007","volume":"20","author":[{"given":"Yulian","family":"Mytsyk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serhiy","family":"Pasichnyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ihor","family":"Dutka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ihor","family":"Dats","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmytro","family":"Vorobets","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micha\u0142","family":"Skrzypczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yerzhan","family":"Uteuliyev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Botikova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarina","family":"Gazdikova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Kubatka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Urdzik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7069-3784","authenticated-orcid":false,"given":"Peter","family":"Kruzliak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,5]]},"reference":[{"key":"612_CR1","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1093\/ije\/dyz136","volume":"48","author":"T Zheng","year":"2019","unstructured":"Zheng T, Zhu C, Bassig BA, et al. The long-term rapid increase in incidence of adenocarcinoma of the kidney in the USA, especially among younger ages. Int J Epidemiol. 2019;48:1886\u201396.","journal-title":"Int J Epidemiol"},{"key":"612_CR2","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s10238-018-0488-3","volume":"18","author":"Z Wang","year":"2018","unstructured":"Wang Z, Peng S, Xie H, et al. Prognostic and clinico-pathological significance of PD-L1 in patients with renal cell carcinoma: a meta-analysis based on 1863 individuals. Clin Exp Med. 2018;18:165\u201375.","journal-title":"Clin Exp Med"},{"key":"612_CR3","doi-asserted-by":"crossref","first-page":"86157","DOI":"10.18632\/oncotarget.21029","volume":"8","author":"T Miao","year":"2017","unstructured":"Miao T, Li Y, Sheng X, Yao D. Marital status and survival of patients with kidney cancer. Oncotarget. 2017;8:86157\u201367.","journal-title":"Oncotarget"},{"key":"612_CR4","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) Research Data (1975\u20132016), National Cancer Institute, DCCPS, Surveillance Research Program, released April 2019, based on the November 2018 submission."},{"key":"612_CR5","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMra1601333","volume":"376","author":"TK Choueiri","year":"2017","unstructured":"Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med. 2017;376:354\u201366.","journal-title":"N Engl J Med"},{"key":"612_CR6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1470-2045(12)70559-4","volume":"14","author":"DY Heng","year":"2013","unstructured":"Heng DY, Xie W, Regan MM, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013;14:141\u20138.","journal-title":"Lancet Oncol"},{"key":"612_CR7","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/cbf.3120","volume":"33","author":"AA Farooqi","year":"2015","unstructured":"Farooqi AA, Siddik ZH. Platelet-derived growth factor (PDGF) signalling in cancer: rapidly emerging signalling landscape. Cell Biochem Funct. 2015;33:257\u201365.","journal-title":"Cell Biochem Funct"},{"key":"612_CR8","doi-asserted-by":"publisher","first-page":"64","DOI":"10.14715\/cmb\/2016.62.14.11","volume":"62","author":"X Lin","year":"2016","unstructured":"Lin X, Khalid S, Qureshi MZ, et al. VEGF mediated signaling in oral cancer. Cell Mol Biol. 2016;62:64\u20138.","journal-title":"Cell Mol Biol"},{"key":"612_CR9","doi-asserted-by":"publisher","first-page":"e0184423","DOI":"10.1371\/journal.pone.0184423","volume":"12","author":"B Amzal","year":"2017","unstructured":"Amzal B, Fu S, Meng J, Lister J, Karcher H. Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: a network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma. PLoS ONE. 2017;12:e0184423.","journal-title":"PLoS ONE"},{"key":"612_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4161\/cbt.9.1.10340","volume":"9","author":"PD Nathan","year":"2010","unstructured":"Nathan PD, Vinayan A, Stott D, Juttla J, Goh V. CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies. Cancer Biol Ther. 2010;9:15\u20139.","journal-title":"Cancer Biol Ther"},{"issue":"Suppl 1","key":"612_CR11","doi-asserted-by":"publisher","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving Considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S\u201350S.","journal-title":"J Nucl Med"},{"key":"612_CR12","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1186\/s12885-017-3371-9","volume":"17","author":"C Kelly-Morland","year":"2017","unstructured":"Kelly-Morland C, Rudman S, Nathan P, et al. Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated 18F-Fluorodeoxyglucose (18F-FDG) positron emission tomography\/magnetic resonance imaging (PET\/MRI); the REMAP study. BMC Cancer. 2017;17:392.","journal-title":"BMC Cancer"},{"key":"612_CR13","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s10238-018-0539-9","volume":"19","author":"V Pankowska","year":"2019","unstructured":"Pankowska V, Malkowski B, Wedrowski M, Wedrowska E, Roszkowski K. FDG PET\/CT as a survival prognostic factor in patients with advanced renal cell carcinoma. Clin Exp Med. 2019;19:143\u20138.","journal-title":"Clin Exp Med"},{"key":"612_CR14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.tranon.2016.01.008","volume":"9","author":"J Antunes","year":"2016","unstructured":"Antunes J, Viswanath S, Rusu M, et al. Radiomics analysis on FLT-PET\/MRI for characterization of early treatment response in renal cell carcinoma: a proof-of-concept study. Transl Oncol. 2016;9:155\u201362.","journal-title":"Transl Oncol"},{"key":"612_CR15","doi-asserted-by":"publisher","first-page":"832.e9","DOI":"10.1016\/j.crad.2018.04.011","volume":"73","author":"I Lavdas","year":"2018","unstructured":"Lavdas I, Rockall AG, Daulton E, et al. Histogram analysis of apparent diffusion coefficient from whole-body diffusion-weighted MRI to predict early response to chemotherapy in patients with metastatic colorectal cancer: preliminary results. Clin Radiol. 2018;73:832.e9\u201316.","journal-title":"Clin Radiol"},{"key":"612_CR16","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1148\/radiol.2016160646","volume":"283","author":"R Perez-Lopez","year":"2017","unstructured":"Perez-Lopez R, Mateo J, Mossop H, et al. Diffusion-weighted Imaging as a treatment response biomarker for evaluating bone metastases in prostate cancer: a pilot study. Radiology. 2017;283:168\u201377.","journal-title":"Radiology"},{"key":"612_CR17","doi-asserted-by":"publisher","first-page":"290","DOI":"10.12659\/PJR.890604","volume":"79","author":"Y Mytsyk","year":"2014","unstructured":"Mytsyk Y, Borys Y, Komnatska I, Dutka I, Shatynska-Mytsyk I. Value of the diffusion-weighted MRI in the differential diagnostics of malignant and benign kidney neoplasms\u2013our clinical experience. Pol J Radiol. 2014;79:290\u20135.","journal-title":"Pol J Radiol"},{"key":"612_CR18","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s11255-016-1460-3","volume":"49","author":"Y Mytsyk","year":"2017","unstructured":"Mytsyk Y, Dutka I, Borys Y, et al. Renal cell carcinoma: applicability of the apparent coefficient of the diffusion-weighted estimated by MRI for improving their differential diagnosis, histologic subtyping, and differentiation grade. Int Urol Nephrol. 2017;49:215\u201324.","journal-title":"Int Urol Nephrol"},{"key":"612_CR19","doi-asserted-by":"publisher","first-page":"100","DOI":"10.2214\/AJR.14.13923","volume":"206","author":"AM H\u00f6tker","year":"2016","unstructured":"H\u00f6tker AM, Mazaheri Y, Wibmer A, et al. Use of DWI in the differentiation of renal cortical tumors. AJR Am J Roentgenol. 2016;206:100\u20135.","journal-title":"AJR Am J Roentgenol"},{"key":"612_CR20","doi-asserted-by":"publisher","first-page":"333","DOI":"10.4137\/CMO.S7263","volume":"5","author":"NS Vasudev","year":"2011","unstructured":"Vasudev NS, Larkin JMG. Tyrosine kinase inhibitors in the treatment of advanced renal cell carcinoma: focus on pazopanib. Clin Med Insights Oncol. 2011;5:333\u201342.","journal-title":"Clin Med Insights Oncol"},{"key":"612_CR21","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s11255-017-1761-1","volume":"50","author":"Y Mytsyk","year":"2018","unstructured":"Mytsyk Y, Dutka I, Yuriy B, et al. Differential diagnosis of the small renal masses: role of the apparent diffusion coefficient of the diffusion-weighted MRI. Int Urol Nephrol. 2018;50:197\u2013204.","journal-title":"Int Urol Nephrol"},{"key":"612_CR22","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s10238-019-00574-7","volume":"19","author":"Y Mytsyk","year":"2019","unstructured":"Mytsyk Y, Borys Y, Tumanovska L, et al. MicroRNA-15a tissue expression is a prognostic marker for survival in patients with clear cell renal cell carcinoma. Clin Exp Med. 2019;19:515\u201324.","journal-title":"Clin Exp Med"},{"key":"612_CR23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.4161\/cbt.9.1.10716","volume":"9","author":"MA Rosen","year":"2010","unstructured":"Rosen MA. Use of modified RECIST criteria to improve response assessment in targeted therapies: challenges and opportunities. Cancer Biol Ther. 2010;9:20\u20132.","journal-title":"Cancer Biol Ther"},{"key":"612_CR24","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1634\/theoncologist.2013-0391","volume":"19","author":"KM Krajewski","year":"2014","unstructured":"Krajewski KM, Franchetti Y, Nishino M, et al. 10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study. Oncologist. 2014;19:507\u201314.","journal-title":"Oncologist"},{"key":"612_CR25","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1097\/RCT.0000000000000848","volume":"43","author":"A Vehabovic-Delic","year":"2019","unstructured":"Vehabovic-Delic A, Balic M, Rossmann C, Bauernhofer T, Deutschmann HA, Schoellnast H. Volume computed tomography perfusion imaging: evaluation of the significance in oncologic follow-up of metastasizing renal cell carcinoma in the early period of targeted therapy - preliminary results. J Comput Assist Tomogr. 2019;43:493\u20138.","journal-title":"J Comput Assist Tomogr"},{"issue":"1053","key":"612_CR26","doi-asserted-by":"publisher","first-page":"20150163","DOI":"10.1259\/bjr.20150163","volume":"88","author":"TY Jeon","year":"2015","unstructured":"Jeon TY, Kim CK, Kim JH, Im GH, Park BK, Lee JH. Assessment of early therapeutic response to sorafenib in renal cell carcinoma xenografts by dynamic contrast-enhanced and diffusion-weighted MR imaging. Br J Radiol. 2015;88(1053):20150163.","journal-title":"Br J Radiol"},{"key":"612_CR27","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/bjc.2013.790","volume":"110","author":"N Bharwani","year":"2014","unstructured":"Bharwani N, Miquel ME, Powles T, et al. Diffusion-weighted and multiphase contrast-enhanced MRI as surrogate markers of response to neoadjuvant sunitinib in metastatic renal cell carcinoma. Br J Cancer. 2014;110:616\u201324.","journal-title":"Br J Cancer"},{"key":"612_CR28","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1053\/j.ro.2014.09.001","volume":"49","author":"L Valls","year":"2014","unstructured":"Valls L, Hoimes CJ, Sher A, et al. Early response monitoring of receptor tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma using [F-18]fluorothymidine-positron emission tomography-magnetic resonance. Semin Roentgenol. 2014;49:238\u201341.","journal-title":"Semin Roentgenol"},{"key":"612_CR29","doi-asserted-by":"publisher","first-page":"4127","DOI":"10.1158\/0008-5472.CAN-17-0248","volume":"77","author":"SP Robinson","year":"2017","unstructured":"Robinson SP, Boult JKR, Vasudev NS, Reynolds AR. Monitoring the vascular response and resistance to sunitinib in renal cell carcinoma in vivo with susceptibility contrast MRI. Cancer Res. 2017;77:4127\u201334.","journal-title":"Cancer Res"},{"key":"612_CR30","doi-asserted-by":"publisher","first-page":"7498538","DOI":"10.1155\/2017\/7498538","volume":"2017","author":"I Leguerney","year":"2017","unstructured":"Leguerney I, de Rochefort L, Poirier-Quinot M, et al. Molecular imaging to predict response to targeted therapies in renal cell carcinoma. Contrast Media Mol Imaging. 2017;2017:7498538.","journal-title":"Contrast Media Mol Imaging"},{"key":"612_CR31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/MOU.0000000000000463","volume":"28","author":"J Weiss","year":"2018","unstructured":"Weiss J, Notohamiprodjo M, Bedke J, Nikolaou K, Kaufmann S. Imaging response assessment of immunotherapy in patients with renal cell and urothelial carcinoma. Curr Opin Urol. 2018;28:35\u201341.","journal-title":"Curr Opin Urol"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-020-00612-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10238-020-00612-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-020-00612-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T13:56:05Z","timestamp":1665755765000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10238-020-00612-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,5]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["612"],"URL":"https:\/\/doi.org\/10.1007\/s10238-020-00612-9","relation":{},"ISSN":["1591-8890","1591-9528"],"issn-type":[{"value":"1591-8890","type":"print"},{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,5]]},"assertion":[{"value":"17 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human participants and\/or animals"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}